Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
C Gómez-Labrador, E Ricart, M Iborra, E Iglesias… - Pharmaceutics, 2024 - mdpi.com
Markers that allow for the selection of tailored treatments for individual patients with
inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in …
inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in …
Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists
S White, R Morrow, I Pan… - Journal of pediatric …, 2023 - journals.lww.com
In January of 2023, the first adalimumab biosimilar became available in the United States for
treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set …
treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set …
Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
TG Bas, V Duarte - Pharmaceuticals, 2024 - mdpi.com
This research is based on three fundamental aspects of successful biosimilar development
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
[PDF][PDF] 10 [Suppl x]: 02-11
N Humphry - DOI/10.33590, 2022 - emjreviews.com
There was an overall feeling at the EORTC-CLTG meeting that further research is needed to
better define the molecular basis for the different forms of cutaneous T cell lymphoma …
better define the molecular basis for the different forms of cutaneous T cell lymphoma …